TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06414590: Neoadjuvant Tebentafusp for Uveal Melanoma

Sponsor: Thomas Jefferson University · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$739,200

Rescue Site Savings

+$508,200

Unlock Full NCT06414590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06414590 Rescue Dossier →